All In Biotech

Drug Trial Radar · NCT04256421

A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab (Anti-Tigit Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 490 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

490

Actual

Start

Feb 4, 2020

Primary completion

Sep 6, 2022

Study completion Jul 31, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Feb 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Eligible participants will be stratified by Eastern Cooperative Oncology Group (ECOG) Performance Status (0 vs. 1), LDH (\</= upper limit of normal \[ULN\] vs. \> ULN), and presence or history of brain metastasis (yes vs. no) and randomly assigned in a 1:1 ratio to receive one of the following treatment regimens during induction phase: * Arm A: Tiragolumab plus atezolizumab plus CE * Arm B: Placebo plus atezolizumab plus CE Following the induction phase, participants will continue maintenance therapy with either atezolizumab plus tiragolumab (Arm A) or atezolizumab plus placebo (Arm B).

Conditions

  • Small Cell Lung Cancer

Interventions

  • TiragolumabDrug

    Tiragolumab 600 milligrams (mg) administered by IV infusion on Day 1 of each 21-day cycle.

  • AtezolizumabDrug

    Atezolizumab 1200 mg administered by IV infusion on Day 1 of each 21-day cycle.

  • CarboplatinDrug

    Carboplatin was administered by IV infusion on Day 1 of each 21-day cycle for 4 cycles.

  • EtoposideDrug

    Etoposide 100 mg/m\^2 administered by IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles.

  • PlaceboDrug

    Placebo administered by IV infusion on Day 1 of each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator-assessed Progression-free Survival (PFS) in the Primary Analysis Set (PAS)Time frame: From randomization to the first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24 months)
  2. Overall Survival (OS) in the PASTime frame: From randomization to death from any cause (up to approximately 24 months)

Locations

121 sites in 23 countries. Site status is shown where the registry gives one.

  • Rocky Mountain Cancer Centers - Lone Tree

    Lone Tree, Colorado

  • MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center)

    Washington D.C., District of Columbia

  • Florida Cancer Specialists

    Fort Myers, Florida

  • SCRI Florida Cancer Specialists North

    Sarasota, Florida

  • Northwest Georgia Oncology Centers PC - Marietta

    Marietta, Georgia

  • Illinois Cancer Care

    Peoria, Illinois

  • New England Cancer Specialists

    Scarborough, Maine

  • Weinberg Cancer Institution at Franklin Square

    Baltimore, Maryland

  • Minnesota Oncology Hematology

    Minneapolis, Minnesota

  • Comprehensive Cancer Centers of Nevada

    Henderson, Nevada

  • Broome Oncology - Binghamton

    Binghamton, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Sarah Cannon Research Institute / Tennessee Oncology

    Chattanooga, Tennessee

  • Sarah Cannon Research Inst.

    Nashville, Tennessee

  • Texas Oncology Cancer Center

    Austin, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Blue Ridge Cancer Care

    Roanoke, Virginia

  • University of Wisconsin School of Medicine and Public Health

    Madison, Wisconsin

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia

  • Nepean Hospital

    Kingswood, New South Wales, Australia

  • Sunshine Coast University Hospital

    Birtinya, Queensland, Australia

  • Lyell McEwin Hospital

    Elizabeth Vale, South Australia, Australia

  • Tiroler Landeskrankenanstalten Ges.M.B.H.

    Innsbruck, Austria

  • Klinik Penzing

    Vienna, Austria

  • Krankenhaus Nord - Klinik Floridsdorf

    Vienna, Austria

  • AZ St Maarten Campus Leopoldstr

    Mechelen, Belgium

  • Clinique Ste-Elisabeth

    Namur, Belgium

  • AZ Delta (Campus Rumbeke)

    Roeselare, Belgium

  • Vitaz

    Sint-Niklaas, Belgium

  • Oncocentro Serviços Médicos e Hospitalares Ltda

    Fortaleza, Ceará, Brazil

  • Hospital Sao Rafael - HSR

    Salvador, Estado de Bahia, Brazil

  • Hospital de Clínicas de Passo Fundo

    Passo Fundo, Rio Grande do Sul, Brazil

  • Hospital Nossa Senhora da Conceicao

    Porto Alegre, Rio Grande do Sul, Brazil

  • Clínica de Oncologia Reichow

    Blumenau, Santa Catarina, Brazil

  • Instituto do Cancer do Estado de Sao Paulo - ICESP

    São Paulo, São Paulo, Brazil

  • Fakultni nemocnice Olomouc

    Olomouc, Czechia

  • Vitkovicka Nemocnice Bma, A.S.

    Ostrava, Czechia

  • Thomayerova nemocnice

    Praha 4 - Krc, Czechia

  • Helios Klinikum Emil von Behring GmbH

    Berlin, Germany

  • LungenClinic Großhansdorf GmbH

    Großhansdorf, Germany

Showing 40 of 121 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.